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A B S T R A C T
Drug release from chemoembolization microspheres stimulated by the presence of a chemically reducing
environment may provide beneﬁts for targeting drug resistant and metastatic hypoxic tumours. A water-
soluble disulﬁde-based bifunctional cross-linker bis(acryloyl)-(l)-cystine (BALC) was synthesised,
characterised and incorporated into a modiﬁed poly(vinyl) alcohol (PVA) hydrogel beads at varying
concentrations using reverse suspension polymerisation. The beads were characterised to conﬁrm the
amount of cross-linker within each formulation and its effects on the bead properties. Elemental and UV/
visible spectroscopic analysis conﬁrmed the incorporation of BALC within the beads and sizing studies
showed that in the presence of a reducing agent, all bead formulations increased in mean diameter. The
BALC beads could be loaded with doxorubicin hydrochloride and amounts in excess of 300 mg of drug per
mL of hydrated beads could be achieved but required conversion of the carboxylic acid groups of the BALC
to their sodium carboxylate salt forms. Elution of doxorubicin from the beads demonstrated a controlled
release via ionic exchange. Some formulations exhibited an increase in size and release of drug in the
presence of a reducing agent, and therefore demonstrated the ability to respond to an in vitro reducing
environment.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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The practice of locoregional delivery of chemotherapeutics
from embolic agents to treat hypervascular tumours has continued
to attract much attention in recent years, with several different
commercial offerings now on the market (de Baere et al., 2016;
Pereira et al., 2016). Product innovation in this area is progressing
by virtue of added functionality being designed into the embolic
agent, such as radiopacity to allow them to be imaged during and
after administration (Duran et al., 2016; Levy et al., 2016) and
biodegradability to allow these agents to disappear over time
(Weng et al., 2011a,b, 2013a; Verretet al., 2014). Regardless of these
added features, the primary mechanism of action of Drug-eluting
Beads (DEB) is to physically block the blood supply and create an
ischaemic insult to solid hypervascularised malignant tumours,
followed by provision of a sustained local release of a chemother-
apeutic agent at the tumour site, in a procedure known as
transarterial chemoembolisation (DEB-TACE) (Liapi et al., 2007;
Malagari 2008; Liapi and Geschwind, 2011; Nicolini et al., 2011;* Corresponding author.
E-mail address: andrew.lewis@btgplc.com (A.L. Lewis).
http://dx.doi.org/10.1016/j.ijpharm.2017.03.084
0378-5173/© 2017 The Authors. Published by Elsevier B.V. This is an open access articlLewis and Dreher, 2012). However, when the microcirculation to a
tumour is blocked, oxygen levels decrease to critically low levels
causing the tumour to become hypoxic. Whilst the ischemia may
kill many of the tumour cells, some may survive within this
hypoxic milieu and are known to become chemoresistant and
secrete growth factors that promote angiogenesis and metastasis
of tumour cells to other parts of the body (Kunz and Ibrahim,
2003).
Hypoxic tumour cells have been shown to overexpress
intracellular glutathione (GSH) (Kuppusamy et al., 2002) which
has been associated with enhanced cellular proliferation (Kang and
Enger, 1990), reduced apoptosis (Hall, 1999) and increased
resistance to chemotherapy (Traverso et al., 2013). The associated
increase in reducing potential compared to normal tissue however,
has been used to target tumour cells intracellularly using a variety
of redox-responsive nanocarriers such as dendrimers (Kurtoglu
et al., 2009), micelles (Lv et al., 2014), polymersomes (Nahire et al.,
2014) and liposomes (Sun et al., 2015). The extracellular tumour
microenvironment is also highly reducing in nature (Bobko, et al.,
2012; Khramtsov and Gillies 2014) and could provide a stimulus for
targeting drug delivery from DEBs delivered intra-arterially and
present in areas of severe hypoxia. Nanoparticulate non-viral
vectors have been developed for gene delivery which comprise ofe under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Chemical structure of N,N’-bis(acryloyl)-(L)-cystine (BALC).
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2010). In this study the investigators used a cross-linker called N,
N’-bis(acryoyl cystamine) in which the disulﬁde link was shown to
be cleaved in a reducing environment to the corresponding thiols
and that the polymer could subsequently mediate gene transfec-
tion (Dai et al., 2010). This same compound has been used to
crosslink ethylenediamine to form a polymer system for the
delivery VEGF to promote neovascular formation in ischemic tissue
by transfecting hypoxic cells (Christensen et al., 2007). Again, the
N,N’-bis(acryoyl cystamine) was reduced in the hypoxic conditions
and VEGF expression was 76 times higher in hypoxic cells than in
normoxic cells (Christensen et al., 2007).
On a larger length scale, protenoid microspheres have been
made from thermally condensed amino acids cross-linked with an
agent containing disulﬁde functionality (Quirk, 2007). The micro-
spheres were able to encapsulate material and release it slowly
when exposed to a reducing agent, the rate of release being
dependent on both the number of cross-links and rates of cleavage.
Similarly, biodegradable polymeric microcapsules based on thiol-
disulﬁde chemistry have been described by Zelkin and prepared
from poly(methacrylic acid) (PMA) cross-linked using layer-by-
layer deposition of thiolated PMA (PMASH) and poly(vinylpyr-
ollidone) (PVP) on silica particles, followed by oxidation of the
thiols to crosslink the PMA and removal of the silica and PVP by
changing the pH to disrupt hydrogen bonding and form a capsular
structure (Zelikin et al., 2005). In a slightly altered form of this
product, the capsules were able to retain their contents in
normoxic conditions, but in the presence of GSH the contents
were released (Chong et al., 2009). Whilst hypoxia-responsive
nano and microspherical carrier systems have therefore been
described previously, to our knowledge, there has not been a report
of a disulﬁde-based microsphere system designed to embolise
vessels and respond to the stimulus of the hypoxic environment of
a solid tumour. Herein we describe the synthesis and characteri-
sation of the ﬁrst embolic hydrogel beads designed to regulate
their drug eluting capacity in response to hypoxic environments.
The design rationale was based upon the reduction of disulﬁde
cross-linking groups, leading to an increase in drug release, with
the intention to saturate the tumour cells and combat the chemo-
resistance associated with those areas of highest ischaemic insult.
2. Materials and methods
2.1. Materials
Solvents used in the synthetic procedures included ethyl
acetate, n-butyl acetate, acetone, dichloromethane (DCM), ethanol,
methanol, dimethyl sulfoxide (DMSO) and propan-2-ol, which
were all purchased from Romil UK Ltd (Cambridge, UK, super
purity solvent grade). Cellulose acetate butyrate (CAB), 2020-azobis
(2-methylpropionamide) dihydrochloride, sodium borohydride
(NaBH4), 5,50-dithiobis-(2-nitrobenzoic acid), dl-dithiothreitol
(DTT), phenolphthalein and universal indicator sticks (pH 0–14)
were all purchased from Sigma-Aldrich UK (Poole, UK). For the
bead synthesis, polyvinyl alcohol (PVA) macromer was manufac-
tured by Biocompatibles UK Ltd (Farnham, UK) using PVA partly
saponiﬁed, 88% hydrolysed,12% acetate content, average molecular
weight of 67,000 Da (Mowiol 8–88, Honeywill & Stein, Ltd. UK) and
N-acryloyl-aminoacetaldehyde dimethyl acetal (NAAADA, Biocom-
patibles UK Ltd, Farnham) by a published method (Lewis et al.,
2008). The N,N’-bis(acryloyl)-(l)-cystine (BALC) was synthesised as
described in Section 2.2 using sodium hydroxide (NaOH), l-cystine
dihydrochloride, 2-methoxyhydroquinone, acryloyl chloride and
4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl free radicals,
(TEMPO) all purchased from Sigma-Aldrich UK. HCl and NaOH
were purchased from Fisher Scientiﬁc, while the water used in allexperiments was puriﬁed at Biocompatibles UK Ltd using a
Millipore Elix 4 type 1 water puriﬁcation system. Frozen section
compound (FSC-22) was purchased from Leica Microsystems and
doxorubicin hydrochloride (Dox) for the drug loading and release
experiments was supplied from Hisun Pharmaceutical Co. Ltd,
China.
2.2. Synthetic methods
2.2.1. Synthesis and puriﬁcation of N,N’-bis(acryloyl)-(l)-cystine
(BALC)
The synthesis of BALC was achieved using a modiﬁcation of the
method described by Emilitri and co-workers (Emilitri et al., 2005).
In this method 12.1 g of cystine dihydrochloride and 15 mg TEMPO
were dissolved in 50 mL of distilled water. The solution was mixed
using an overhead stirrer (350 rpm) and then cooled and kept
between 0 and 5 C using a salt ice bath. 6 M NaOH was then added
drop-wise to adjust the solution to pH 10–12 followed by the drop
wise addition of 8.1 mL acryloyl chloride solution dissolved in
10 mL dichloromethane. The mixture was stirred at room
temperature for 3 h. The solution was then adjusted to pH 1–2
using 2 M HCl, frozen over night at 20 C and then freeze dried.
DCM (75 mL) was then added to the resulting white powder and
mixed. The DCM was discarded and the remaining solid was
dissolved in methanol. The solution was ﬁltered through a sintered
funnel and placed onto a rotary evaporator until a product was
obtained.
DCM (3  30 mL) was added to the resulting white powder
obtained after synthesis to remove residual acrylic acid. The DCM
solution was passed through a sintered funnel and discarded. The
remaining BALC was dissolved in 3  50 mL acetone and the
solution passed through a sintered funnel to remove NaCl. The
ﬁltered solution was rotary evaporated to remove the acetone. To
purify the material, silica gel chromatography was used to separate
the BALC from salt and other potential impurities. Silica gel was
added to the BALC solution (5–10 mL) until all the solution
absorbed on to the gel. A column was dry packed with silica gel and
washed with ethyl acetate solution. The BALC mixture was then
packed down evenly on top of the column. Silica gel was then
added on top of the mixture to protect the surface. The column was
then washed twice with ethyl acetate and the eluent changed to a
3:1 ratio of acetone:EtOAc. The fractions of eluent were collected
and placed on a rotary evaporator to remove the solvent. The
product was allowed to dry under vacuum over 24 h. The ﬁnal
product was characterised by 1H NMR, 13C NMR, 2D correlation
spectrometry (2D COSY), Distortion Enhancement by Polarisation
Transfer-135 (DEPT-135) and Nuclear Overhauser Effect Spectros-
copy (NOESY), electrospray mass spectroscopy and elemental
analysis. Characterisation data were fully consistent with BALC
structure (Fig. 1) (Emilitri et al., 2005).
2.2.2. Synthesis of BALC beads
The synthesis of the beads was based on a method used to
manufacture DC Bead1 (Lewis et al., 2008). A 1 Litre jacketed
reaction vessel was ﬁlled with 600 g n-butyl acetate and 11.5 g CAB
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sufﬁcient mixing and for the organic phase to be purged with
nitrogen. An over-head stirrer was set to 400 rpm and the vessel
was maintained at 30 C. After the organic phase had been purged,
nitrogen was placed above it to form a N2 blanket.
BALC was dissolved in water to prepare the aqueous phase, the
amount of monomer added being dependent upon the desired
degree of incorporation in the polymer formulation (0–80 wt%).
The BALC solution was then added to 100 g PVA macromer solution
(21% w/w) and mixed thoroughly, except for the 0 wt% BALC
formulation which was made using exactly the same method but
without BALC added to the formulation. The macromer was
manufactured in-house using a process by which N-acryloylami-
noacetaldehyde (NAAADA) was attached to PVA chains by trans-
esteriﬁcation (Lewis et al., 2008). The thermal initiator 2020-azobis
(2-methylpropionamide) dihydrochloride (10 mg/mL for formula-
tions 0–15 wt% BALC and 1 mg/mL for 31 wt% BALC) was mixed
with the BALC and macromer. The aqueous phase was then added
to the organic phase and the temperature of the vessel increased to
80 C. The reaction was allowed to continue for 2 h.
Once the reaction was complete the organic phase was removed
from the vessel leaving the newly formed microspheres. A cleaning
process to remove the organic phase was carried out by three
sequential washes with 125 mL of ethyl acetate, three washes with
250 mL of acetone, followed by ﬁltration using a sintered funnel to
remove the acetone. The collected microspheres were washed with
puriﬁed water in order to remove the acetone and hydrate the
beads fully. Once the beads were fully washed they were passed
through a number of different size stainless steel sieves (Fisher
Scientiﬁc UK) in order to separate the BALC beads into different
size groups. The beads were passed through a sieve stack with the
assistance of a recirculating water loop pressurising the beads
through the sieves. The microspheres were hydrated in water for
characterisation studies. The proposed generic chemical structure
for BALC Beads is shown in Fig. 2.Fig. 2. Proposed chemical structure for BALC Beads (where the values for x, y and z
are dependent upon the various weight ratios of PVA macromere to BALC in the
reaction mixture).2.3. Characterisation methods
2.3.1. Elemental analysis
Elemental analysis was conducted on the dried beads by Medac
Ltd. (UK). Beads from each formulation (1 mL) were placed in a
glass vial. The water was removed, the beads frozen and the vial
placed on a Copley Heto drywinner freeze dryer for 24 h. The vial
lids were modiﬁed with a semi-permeable membrane allowing
removal of water but retaining beads with the vials. A minimum of
200 mg in each vial was prepared for analysis. The beads subjected
to combustion analysis for carbon, hydrogen, nitrogen and sulfur
(C, H, N & S) (N = 2) performed on a Thermo EA1108 or FlashEA1112
series elemental analyser. The accuracy of the results were within a
0.30% absolute and the detection limit for each component is
<0.1% according to the service provider. The theoretical elemental
composition used in Table 1 was calculated from the target
composition used in the synthesis of each formulation and
assuming a 100% conversion of all components.
2.3.2. Energy Dispersive X-ray spectroscopy-sulfur mapping (EDX)
EDX was used to map the sections of the disulﬁde cross-linker
throughout the bead (Ashraﬁ et al., 2017; Hagan et al., 2017). The
BALC bead sections were prepared ﬁrstly by obtaining 10 mm
sections from the centre of the beads with the use of a cryostat
(Leica CM1860). This was prepared by freezing BALC beads in a PVA
gel (FSC-22) on a sample stub. The stub was placed in a cryostat and
10 mm sections cut. The sections were mounted on to a glass slide
and, as the samples were electrically non-conducting, sputter
coated with vacuum–evaporated carbon using a Quorum Q150T
sputter coating system. The coated samples were placed in the SEM
chamber (Zeiss Sigma FEG) and viewed using an accelerating
voltage of 10 KeV. Using the X-ray spectrometer attached to the
SEM, the elements within the hydrogel were mapped.
2.3.3. Bead sizing
A sample of beads (1 mL) was placed in a glass dish and
observed using an Olympus BX50 microscope with an attached
ColorView III camera. Sizing was performed manually using the
sizing tool of AnalySIS software (Soft imaging system GmbH). A
population of 200 beads was chosen at random throughout the
dish and the diameter of each bead in the sample measured (Lewis
et al., 2006a,b).Table 1
Elemental analysis of a range of BALC bead formulations.
Formulation C H N S
0% BALC Theoretical% 52.2 9.1 0.7 0.0
Measured average (n = 2) % 52.2 9.0 0.3 <0.1
2% BALC Theoretical% 54.2 9.0 0.4 0.4
Measured average (n = 2) % 54.4 9.1 0.4 1.1
4% BALC Theoretical% 53.1 8.8 1.7 0.9
Measured average (n = 2) % 51.9 8.7 1.2 1.3
8% BALC Theoretical% 53.3 8.7 0.9 1.6
Measured average (n = 2) % 53.1 8.8 0.8 1.9
15% BALC Theoretical% 51.8 8.4 2.4 2.8
Measured average (n = 2) % 50.7 8.3 1.9 2.7
31% BALC Theoretical% 50.2 7.6 2.8 6.1
Measured average (n = 2) % 48.6 7.4 2.9 6.1
45% BALC Theoretical% 48.6 7.1 3.7 8.3
Measured average (n = 2) % 45.8 7.3 3.7 8.0
60% BALC Theoretical% 46.6 6.4 4.9 11.0
Measured average (n = 2) % 42.7 6.3 4.7 9.7
80% BALC Theoretical% 43.9 5.5 6.5 14.8
Measured average (n = 2) % 40.4 5.5 6.2 13.7
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beads
BALC incorporation into the polymer structure was analysed
using a method adapted from Dai et al. (2010). BALC beads (1 mL)
were placed in 2 mL of water. 1 mL of a control PVA macromer
beads was prepared in the same manner. The beads had 1.5 mL of
NaBH4 added to the vials which were then placed in a water bath
at 37 C and left for one hour. 5 M HCl (200 mL) was then added to
the reaction mixture to consume the remaining NaBH4 followed
by the drop-wise addition of 1 M NaOH to neutralise the HCl. The
solution was raised to pH 8 with NaOH. 5,50-dithiobis-(2-
nitrobenzoic acid) (DTNB or Ellmans reagent) was prepared at
a concentration of 0.08 mg mL1 (Dai et al., 2010). DTNB solution
(3 mL) was added to each vial and left to incubate for 30 min in the
water bath at 37 C. After 30 min the samples were removed and
analysed using a Varian Cary 50 UV/Vis spectrophotometer
scanning the range of 300–500 nm for the 2-nitro-5-thiobenzoate
anion (NTB).
2.3.5. Investigation of the effect of reduction on bead size and
degradation
In order to evaluate the effect of reducing conditions the BALC
beads were placed in a glass vial and 1 mL of 4% dithiothreitol (DTT)
was added. The vials with microspheres were placed in a water
bath at 37 C and left for one hour followed by washing (x 5) with
deionised water (20 mL) to wash out remaining DTT. Once the
beads were hydrated in water they were placed under the
microscope again and another 200 measurements of the diameter
were recorded.
Potential degradation of BALC formulations from 0 to 80% was
evaluated by dispensing samples of each bead type (0.5 mL) into
Millipore centrifuge tubes with inserts of a 5 mm pore mesh on the
bottom. Four inserts were set aside for each formulation for each
time point. The beads were placed in the removable inserts from
the centrifuge tubes. The samples were placed in a minifuge and
centrifuged at 6000 g. The samples were spun for 15 s (twice) to
remove any excess solution through the bottom mesh. Once the
solution was removed the inserts were weighed on a calibrated
balance noting the starting wet weight of the beads (insert weight
already noted). Then 1 mL of 7 mM DTT solution in PBS was added
to each sample, the tubing sealed and placed in an oven at 37 C.
The DTT solution was removed from the beads at a 7 day time point,
with 1 mL of fresh 7 mM DTT solution added. This was repeated
every 7 days for the duration of the experiment.
The bead samples at each sampling time point were then
placed in the minifuge, removing the excess DTT solution by
centrifuging for 15 s (twice). The inserts were placed on the
balance taking the post incubation wet weight of each sample
(n = 4). Three of the samples were then placed in a vacuum oven at
50 C overnight to obtain the dry mass of the volume of beads.
The 4th sample was hydrated in water and analysed under
the light microscope and was also sized using the method
previously described. Images of the bead were then taken with an
Olympus BX50 microscope and ColorView III camera for visual
analysis.
2.3.6. Bead water content determination
Gravimetric analysis was used to establish the water content of
the various formulations of beads. One gram of the beads was
weighed on pre-weighed aluminium trays. Excess water was then
pipetted away from the beads. The beads were placed in an oven at
60 C under vacuum and weighed repeatedly until there was no
change in their weight. This point was taken as the dry weight of
the microspheres. From these measurements Equilibrium Water
Contents (EWC) and the corresponding solids content of the
various hydrated bead formulations were be obtained.2.3.7. Loading of doxorubicin
The method of drug loading into the beads was based on that
described by Lewis et al. (2007). A Dox solution was prepared at
25 mg/mL in deionised water. The pre-calculated theoretical
maximum loading capacities of the BALC microsphere were used
to determine the maximum amount of drug to be added. An excess
of the maximum value of the drug solution was chosen and placed
within all the vials, irrespective of binding capacity, to ensure
maximum binding and consistency. Each 1 mL of BALC bead (700–
900 mm size fraction) was immersed in approximately 3 mL of Dox
solution. The vials of beads were then placed on a shaker at
200 rpm and left overnight at room temperature. After loading of
the drug into BALC beads, it was necessary to determine the precise
amount of drug loaded within the beads. This was performed by
washing away unbound drug with deionised water. Initially all the
free drug solution was removed using a glass pipette and placed in
separate glass vials ensuring no beads were removed. The collected
drug solution was kept in glass vials for analysis. Deionised water
(10 mL) was then added to the vials to remove any residual drug.
Following washing, the added deionised water was removed and
collected and 10 mL of fresh deionised water was added. This
process was carried out repeatedly until freshly added water was
no longer tainted red by the Dox solution. The collected wash
solutions of initially removed drug were then analysed on a Varian
Cary 50 UV/Vis spectrophotometer at 483 nm. Using a calibration
curve, the concentrations were then added together from each
wash cycle to give the amount of drug not taken up by the beads.
This was then deducted from the total amount added to give the
ﬁnal value of the maximum binding capacity. Theoretical dox
loading was calculated based upon the BALC content present
derived from the actual elemental compositions of the bead
formulations obtained (Table 1) and the solids content present in
each of the corresponding hydrated bead formulations (Sec-
tion 2.3.6), together with the assumptions that beads would pack
to a 77.8% efﬁciency in solution (Hales, 1992) and that one
carboxylic acid group from the BALC would interact with one dox
molecule.
2.3.8. Determination of drug binding sites within BALC beads
An acid-base titration was performed to determine the
amount of carboxylic acid groups within the beads and hence
the potential maximum drug loading capacities. This was
performed by neutralising the acid attached to the beads with
a known concentration of base, therefore quantitatively deter-
mining the concentration of unknown acid binding sites within
the beads. BALC beads (1 mL) were mixed with 1 mL of 1 M HCl
(n = 3), to ensure that all sites were in their acid form. The beads
were then washed and agitated in deionised water (20 mL) to
remove any free acid. The beads were then collected and placed
into a conical ﬂask with 20 mL of deionised water. Two drops of 1%
phenolphthalein solution (in propan-2-ol) were added to the
conical ﬂask with the beads and the ﬂask contents were stirred
with a magnetic ﬂea. The titrant used in the reaction was 0.005 M
NaOH and this was added using a burette with the titrant added
drop wise. The sample was then left to equilibrate by mixing.
This method continued until the equivalence point was reached
and all the acid groups had disassociated-indicated by a colour
change when the solution turned from clear to a pink colour
and the change was permanent. The amount of NaOH added
was recorded. This method was repeated with the same
formulation of beads that were washed with deionised water,
rather than acid.
2.3.9. Binding site neutralisation loading technique
Further drug loading studies were performed where 1 mL of
BALC beads were placed in 1 M NaOH solution and left for 20 min.
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washed with deionised water to remove any residual NaOH. The
beads were then loaded according to the same method used in
2.3.7. The BALC beads were immersed in excess Dox solution and
allowed to load on a mixing plate over-night. After 24 h, all excess
drug loading solution was removed and analysed by UV.
2.3.10. Drug release from BALC beads
The drug release of BALC beads was performed in triplicate on
samples as prepared in 2.3.7. Dox loaded BALC beads (1 mL) were
removed from the packing solution and washed in water to
remove any excess drug. The water was then removed and the
beads left in slurry until the start of the experiment. Using the
release media, Dox loaded BALC beads were washed out of the
vials and added to a sealable, light-protected vessel with 200 mL
of PBS. Another 1 mL of Dox loaded BALC beads of the same
formulation was placed in a sealable, light-protected vessel with
200 mL PBS and 60 mM DTT reducing agent (Meng et al., 2009;
Shirazi et al., 2011) at 37 C. At set time points of 10, 30, 60, 120,
240, 360 and 1440 min, 5 mL of the solution was removed and
placed in a glass vial for analysis. Then a fresh 5 mL of either PBS
or PBS with reducing agent was added to the respective vessels.
Some Dox loaded BALC bead formulations were added to a larger
volume of 500 mL PBS, with the same conditions, described
above, applied. The eluted materials collected from the vessels
were analysed again using UV/Vis spectroscopy (Varian Cary 50
UV/Vis spectrophotometer, UK) at 483 nm. Using a calibration
curve, the concentrations were determined from each sample
point to determine the amount of drug released from each BALC
bead formulation.Fig. 3. Example formulations containing 15 (a), 31 (b), 45 (c) and 80 wt% BALC. Top 
micrograph of bead sections; Bottom row: SEM-EDX sulfur mapping image (individual3. Results
3.1. Bead synthesis and characterisation
With some modiﬁcations to the published synthetic method,
sufﬁciently large yields of BALC were prepared that allowed
multiple suspension polymerisation reactions to be performed
yielding a range of bead formulations with different BALC contents.
The beads were mechanically sieved into size fractions and most
the experimental work was carried out with 700–900 mm size
range, as the largest volume of beads was collected in most
instances from this fraction. The BALC cross-linker proved to be
very soluble in the aqueous phase, allowing preparation of beads
with BALC contents up to 80 wt%. It was noted however, that
formulations of greater than 30 wt% BALC had a tendency to begin
to precipitate during polymerisation, which was solved by
reducing the initiator concentration in the formulation from 10
to 1 mg/mL. Spherical and smooth hydrogel beads were produced
in good yield from the suspension polymerisation of various
formulations ranging from 0 to 80 wt% BALC with PVA macromer
(Fig. 2). The incorporation of the BALC monomer was shown to be
efﬁcient in all cases with elemental sulfur analyses corresponding
closely to the theoretical compositions, albeit a little higher than
predicted for the very lowest BALC contents (Table 1).
Optical microscopy of the beads showed that all formulations
ranging from 0 to 45% BALC had a similar smooth and round
morphology with optical transparency and no colour hue (see
Fig. 3 top row (a)–(c) for examples of the 15, 31 and 45 wt% BALC
formulations). The 60 and 80% formulations were still transparent
but with a notable yellow tint and the hint of tiny particulates
inside the bead structure (see Fig. 3 top row (d) for the 80 wt% BALCrow: Optical micrographs (scale bars = 1000 mm); Middle row: scanning electron
ly scaled).
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the 0–31% BALC beads showed them to be of relatively high water
content ranging from 92 to 97.6% (Fig. 4). This is evident from the
optical micrographs in Fig. 3 whereby these softer, swollen beads
deform slightly under their own weight, the bottom of the bead
contacting the bottom of the glass dish to give the appearance of an
inner spherical area resembling frogspawn. The solids content of
beads >45 wt% BALC was higher, producing a stiffer structure for
which this contact phenomenon is less evident. Moreover, whereas
the 0–45%wt BALC formulations were successfully sieved into size
fractions (as seen by the uniformity of size in the optical
micrographs in Fig. 3, top row (a)–(c)), formulations >45% wt%
were more friable to handle and could not be sieved without
signiﬁcant fragmentation of the beads (hence the range of beads
sizes present in the optical micrograph for the 80 wt% BALC
formulation in Fig. 3, top row (d)).
Beads of each formulation were embedded and sectioned using
a microtome to produce a thin section for SEM-EDX elemental
mapping analysis. The softer formulations proved difﬁcult to
section without the microtome blade forming “chatter-line”
artefacts (Fig. 3, middle row (a)–(c)) whereas the stiffer 80%
formulation produced a smooth, evenly cut surface. Subsequent
SEM-EDX analysis was still possible and revealed no sulfur present
for the 0% formulation as expected (not shown), whereas there
were uniform distributions of increasing sulfur content for the
BALC formulations, consistent with their proposed BALC concen-
tration and the elemental analysis presented in Table 1.
3.2. Effects of a reducing environment on the BALC beads
To demonstrate that the disulﬁde bond of the BALC had remain
intact during the synthesis of the beads, the compound 5,50-
dithiobis(2-nitrobenzoic acid) (DTNB, or Ellman’s reagent) was
added to a sample of the beads and observed for any colour change.
DTNB is used to quantify the amount of thiol groups within a
sample, as they will cleave the disulﬁde bond within the DTNB to
give NTB, which ionizes to the yellow-coloured NTB2 dianion in
water at neutral and alkaline pH (Fig. 5(b)) (Chen et al., 2008). In
this case no colour change was noted and conﬁrmed that the
disulﬁde groups had remained intact within the bead structure.
NaBH4 was chosen as the reducing agent as it can be easily
removed from the system by the addition of acid (Hansen et al.,Fig. 4. Variation in Equilibrium Water Co2007). After reduction of the bead sample, the reducing agent was
thoroughly washed away, ensuring none was left in the beads, as
the reducing agent could yield a false result by reducing the DTNB
directly (Hansen et al., 2007). Testing again with DTNB demon-
strated an immediate colour change to yellow for all formulations
containing BALC following reduction (Fig. 5(a), insert images). UV–
vis spectrophotometry using a cuvette of sedimented beads
demonstrated the shift in the lmax for unreacted DTNB at
323 nm in the 0% BALC formulation, to 410 nm for the NTB2
dianion generated for the BALC containing formulations, the
absorbance increasing in conjunction with increasing BALC
content (Fig. 5(a)).
The diameters of beads from a range of BALC formulations that
had been selected from the 700–900 mm sieve fraction were
measured optically to obtain a size distribution histogram. The
beads were then exposed to DTT in order to reduce the disulﬁde
bonds cross-linking the structure, thoroughly washed and then the
size distribution was measured again. In the 0 wt% BALC bead
formulation there was no statistical difference between the size
distributions before and after exposure to the reducing environ-
ment (Fig. 6(a), Table 2). In the case of those formulations
containing BALC, the bead size distribution was seen to increase by
a statistically signiﬁcant amount following reduction (P < 0.05 in
all cases, see Fig. 6(b) for example of the 45 wt% BALC beads).
Table 2 shows the mean sizes for formulations from 0 to 45 wt%
BALC pre and post reduction and the percentage increase in the
diameter. In general, the higher the percentage of BALC the greater
the percentage increase in the mean bead diameter following
reduction. For the lower BALC formulations, the increase in size
post reduction is 10-14% as entanglement of the higher levels of
PVA chains in the structure will limit the bead swelling. With much
higher levels of BALC in the composition (and hence lower
amounts of PVA), the effect of cleavage of the cross-linking points
is more predominant than the PVA chain entanglement and the
increase in bead swelling is more dramatic post reduction.
When beads are incubated with DTT to induce a hypoxic
environment over several weeks, changes to the beads could be
monitored by measuring weight loss and their appearance under
the microscope. Fig. 7(a) shows the loss in mass over 64 days for 0–
80 wt% BALC bead formulations, which was minimal over the ﬁrst
3 days. At 7 days the 45 wt% formulation had >20% weight loss
which accelerated to >50% at 21 days, >90% at the 42 and 64 dayntent with BALC content in the bead.
Fig. 5. UV–vis Spectra for bead formulations ranging from 0 to 15 wt% BALC reduced using NaBH4 and then treated with DTNB. Generation of the yellow colour indicates the
presence of thiol groups in the bead structure arising from reduction of the disulﬁde cross-links. (For interpretation of the references to colour in this ﬁgure legend, the reader
is referred to the web version of this article.)
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Fig. 6. Bead size distribution histograms for (a) 0 wt% BALC beads and (b) 45 wt%
BALC beads pre and post reduction with DTT.
Table 2
Mean diameters of BALC Beads Pre and post reduction with percentage change (mm) (
BALC Formulations 0% 2% 4%
Pre-Reduction 705  57 856  62 81
Reduced 704  62 955  47 93
% Change 0.1 10.3 13
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Whilst formulations <45 wt% BALC follow a similar trend the
degradation was slower the lower the BALC content. The 31 wt%
BALC beads for instance had >70% mass loss but appeared as a
sticky mass of beads in the optical micrograph at 64 days, which is
typical for BALC beads as they degrade. The 15 wt% BALC beads still
looked largely intact at day 64 despite 65% mass loss, although
some slight deformation of the spherical shape was evident. The
0 wt% BALC also showed some mass loss, although the beads
appeared largely intact at 64 days, as unreacted PVA macromer was
lost from the structure. This was supported by the fact that no more
mass loss was experienced over several years’ storage (data not
shown). Oddly, although the 80 wt% BALC formulation clearly
showed signs of stickiness at 21 and 42 days, the mass loss was
minimal. Yet by 64 days degradation was complete.
3.3. Drug loading studies with BALC Beads
When the BALC Beads were immersed in a doxorubicin solution
above that of their theoretical maximum loading, the beads
actively sequestered the drug from solution, turning a uniform red
colour indicative of homogeneous drug loading (see Fig. 8 (a + b)
for an example with 45 wt% BALC beads). Bead morphology
remained smooth and spherical for all formulations and the
average bead size was seen to decrease with dox loading by 25–30%
(Fig. 8(c), similar to DC Bead1). Interestingly, upon placing the
loaded beads in a reducing environment, the average diameter ofmean  SD, n = 200).
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Fig. 7. Degradation of 0–80 wt% BALC bead formulations over 64 days monitored by
(a) mass loss and (b) optical microscopy (scale bars = 1000 mm).
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drug loading and reduction of the disulﬁde links (Fig. 8(c)).
When comparing the maximum dox loading achieved for each
BALC bead formulation with that of the theoretical maximum
(Table 3), the two ﬁgures agree within error for formulations from
0 to 15 wt% BALC and where they exceed 100% is due to a slightly
higher incorporation of BALC than targeted. For formulations
31 wt% BALC, the amount of dox loaded is 20–50% less than the
predicted theoretical amount. An acid-base titration was carried
out for each formulation to conﬁrm the number of drug binding
sites and yielded results close to that of the theoretical maximum
5%. There is therefore a clear disparity between the actual
number of binding sites in the 31 wt% BALC formulations and the
amount of dox that these beads can bind.
In a further drug loading experiment, 60 wt% BALC beads were
reduced prior to the addition of dox. The beads were then washed
to remove the reducing agent and the drug added. The measured
maximum loading capacity was signiﬁcantly greater when
compared to those loaded prior to reduction (126 mg/mL of dox
(n = 3) if reduced, compared to 93.8 mg/mL if pre-reduction). This
result represents a 34% increase in the drug loading capability of
the device attained by cleaving the disulﬁde units in the bead
structure, with now 52% of drug binding sites accessed. It should
also be noted that beads synthesised from BALC have carboxylic
acid residues in their acid form, which are weak acids and will not
be completely ionised at the pH used to bind the dox. Anexperiment was performed in which the acid groups were
converted to their sodium salt form following the protocol in
Section 2.3.9. In this case, the dox loading capacity of 80 wt% BALC
beads was shown to increase from the 109 mg/mL found for those
in the acid form, to 322 mg/mL. This represents an increase from
22% to 66% drug binding site access when the sodium salt form is
used.
Dox elution from BALC bead formulations was evaluated and
compared to that achieved with a commercial standard product,
DC Bead1. Under these test conditions, drug release rates were
dominated by the drug solubility in the limited elution volume and
therefore similar total amounts of drug were released in each case
(Fig. 9). When release was compared using DC Bead1 in both
unreduced and reduced conditions, as anticipated, there was no
difference between the elution curves obtained. For comparison
and demonstration of proof of concept, we select the example of
the 31 wt% BALC formulation, where there was a clear difference in
the rate of release over the ﬁrst 400 min, the reduced BALC bead
releasing dox more quickly in the initial phase (about a 28%
increase in dox), although the eventual cumulative release of drug
eventually reaches a plateaux for both the unreduced and reduced
beads at around 1500 min.
4. Discussion
Disulﬁde chemistry has been frequently employed as a strategy
to target reducing environments. There have been many reports of
polyplex formulations for instance (Polymer and nucleic acid
interpolymer complexes), that have been designed to undergo
cleavage of the disulﬁde linkage under reducing conditions,
facilitating release of the nucleic acid payload (Wang et al.,
2006; Peng et al., 2008; Son et al., 2011). A further important
advantage of such systems has been the low levels of cytotoxicity
achieved when disulﬁde cross-linkers are introduced into delivery
systems (Li et al., 2012; Liu et al., 2012; Shi et al., 2012; Vader et al.,
2012). Hence, due to the low cytotoxicity, biocompatibility,
stability, reducibility and hence ability to target a reducing
environment, disulﬁde functional group chemistry was the route
of choice selected in order to engineer redox-sensitivity. At the
outset of this work we looked to identify a disulﬁde compound that
carried bifunctional vinylic groups to enable copolymerisation
with a preformed polyvinyl alcohol (PVA) macromer that is the
basis of DC Bead1, a well-established drug-eluting embolic
microsphere with over a decade of clinical usage and proven
safety proﬁle. In an initial feasibility study, the compound N,N’-bis
(acryoyl cystamine), which has been described previously in a
number of reported systems (Christensen et al., 2007; Dai et al.,
2010), was of limited success due to poor solubility of this
compound in the aqueous phase of the suspension polymerisation
(Ashraﬁ, 2014). N,N’-bis(acryloyl)-(l)-cystine (BALC) was identiﬁed
as an alternative option which possessed acidic groups that offered
the potential of overcome the solubility issues (Fig.1). Moreover, as
carboxylate groups have been utilised previously in a number of
drug eluting embolic bead compositions to provide drug binding
sites (de Baere et al., 2016; Pereira et al., 2016), the presence of
these groups in BALC could also potentially introduce drug-binding
capability into the bead formulations without the need for
additional ionic comonomers. The carboxylic acids lose their
protons in water leaving them negatively charged (Hoigné and
Bader, 1983), allowing them to bind positively charged drugs such
as doxorubicin hydrochloride which has a positively charged
amine group on its sugar moiety (Grosso et al., 2008).
Suspension copolymerisations appeared to be feasible with a
wide range of BALC contents (Fig. 2), although microscopy revealed
a suggestion of some very ﬁne particulate formation in the higher
BALC compositions (Fig. 3). This was thought to be crosslinked
Fig. 8. Optical micrographs of (a) 45 wt% BALC beads and (b) Dox-loaded 45 wt% BALC. (c) Size distributions of 45 wt% BALC beads: unloaded unreduced; loaded unreduced;
loaded and reduced.
Table 3
Theoretical versus actual maximum dox loading capacity for a range of BALC beads.
% BALC Bead 0% 2% 4% 8% 15% 31% 45% 60% 80%
Theoretical
Dox mg/mL
0 4.9 6.4 11.2 14.6 68.9 51.8 243.1 489.7
Actual
Dox mg/mL
2.1 5.4 8.5 11.3 14.7 15.3 25.0 93.8 109.0
Theoretical No. of Binding Sites/mL NA 8.45 106 11.03 106 19.31 106 25.17  106 11.88  105 89.31 106 41.91 104 84.43  104
Actual No. of Binding Sites Accessed/mL NA 9.31 106 14.55 106 19.48  106 25.34 106 26.38  106 43.1 106 16.17  104 18.79  104
% Binding Sites Accessed NA 110 133 101 101 22 48 39 22
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higher initiator levels, which would have tended to favour more
frequent chain termination over longer chain network formation.
Successful bead fabrication and elemental analysis conﬁrming
achievement of target composition (Table 1) demonstrated that,
despite BALC being a relatively short bifunctional cross-linker, its
acrylamide functional groups could participate favourably in free-
radical copolymerisation with both other BALC monomer and the
PVA macromer to form stable, swollen hydrogel beads which were
transparent and mostly colourless in appearance (Fig. 3). The
transparency suggested that no phase-separation was occurring
during the synthesis, a phenomenon that has been observed in this
type of suspension polymerisation with other water-soluble
monomers (Heaysman et al., 2016, 2017). This was conﬁrmed by
SEM-EDX which showed an homogeneous sulfur distribution
within the bead interior for the various formulations synthesised
(Fig. 3). Water content was seen to range between 93 and 97.5% for
0–15 wt% BALC formulations as there is a balance between the
added hydrophilicity and the increase in cross-linking. For
formulations >15 wt% BALC the EWC began to decrease (andhence solids content of the beads increase) more signiﬁcantly as
cross-linking density became the more predominant effect on
constriction of the swelling of the hydrogel matrix (Fig. 4). Under
normoxic conditions, the BALC incorporated in the bead was stable
in its disulﬁde form, effectively covalently cross-linking the
structure and able to resist the swelling forces within the hydrogel
(Maitra and Shukla, 2014). When a reducing agent was added
however, the disulﬁde bridges were cleaved, each forming two
thiol groups (conﬁrmed by the reduction of Ellman’s reagent to
produce a visible yellow colouration, Fig. 5). The cleavage of the
disulﬁde bridges led to a relaxation of the previously constrained
polymer network, allowing the BALC beads to swell to an increased
bead diameter (Fig. 6 and Table 2).
The PVA macromer has on average only about 7 NAAADA
acrylamide functionalities per polymer chain. Homopolymerisa-
tion of the macromer (0 wt% BALC formulation) did result in the
formation of microspheres but it was noted that over an incubation
period of 64 days some of the PVA had not become incorporated
into the structure and diffused out of the cross-linked matrix,
leaving an insoluble microsphere network that was stable to any
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60 wt% BALC, the higher the BALC content, the faster rate of
degradation of the bead structure; the disulﬁde bonds were
becoming completely cleaved and the polymer chain fragments
gradually extracted from the diminishing network matrix (Fig. 7).
Interestingly, the 80 wt% BALC composition is very highly cross-
linked and maintained its structure with little mass loss up to
42 days despite the disulﬁdes cleaving over the incubation period.
At 64 days however, sufﬁcient chain cleavage had occurred that the
entire network had dissolved away demonstrating complete
degradation within a 2 month in vitro incubation time in a
reducing environment. This property of the BALC Beads makes
them an attractive option as a tumour embolising device, as there
is a great deal of current focus on the design of bioresorbable
embolic bead systems (Weng et al. 2011a,b; Owen et al. 2012;
Weng et al. 2013a,b,c; Verret et al. 2014) because treating
physicians feel this may be advantageous for repeat treatments
requiring re-access via the same vessels.
Dox was shown to interact with the BALC beads (Fig. 8), the
drug loading capacity increasing with increasing content of BALC
as this component carries the carboxylic acid drug binding sites
(Table 3). Interaction of with the drug resulted in a reduction of the
mean bead size by 25–30%, a phenomenon observed previously
with DC Bead1 due to displacement of water from the hydrogel
matrix and tightening of the structure (Lewis et al., 2006a,b, 2007).
Whilst formulations containing up to 15 wt% BALC loaded close to
their theoretical maximum of drug, the high percentage for-
mulations only loaded between 20 and 50% of the theoretical value.
An acid-base titration demonstrated the theoretical number of
binding sites were indeed present in the bead formulations and
could interact with small ions during the titration but not with thelarger drug molecules. The reasons for this were shown to be
twofold: Firstly, conversion of the carboxylic acid groups to the
sodium salt form was shown to increase the amount of drug that
could interact, as the binding sites do not interact with the drug in
their acid form. Secondly, it was shown that if the beads were
reduced prior to drug loading, an increase in drug loading capacity
was attained relative to the unreduced beads, as more of the
binding sites could be accessed in the more swollen, less cross-
linked hydrogel matrix upon disulﬁde cleavage. The higher the
BALC content, the more cross-linked the structure with a reduction
in the macromolecular mesh size available for drug diffusion
(Brown, 2008). BALC beads were therefore shown to have the
potential for high drug loading capacity in the range 300 mg/mL
dox, which is much higher than the current commercially available
embolic microspheres.
Elution of the drug from the BALC-containing systems was far
more complex than we anticipated and whilst discussed in more
detail elsewhere (Ashraﬁ, 2014) is beyond the scope of this
feasibility study. The pH of the elution medium, salt concentration,
volume of eluent and effect of the DTT reductant were found to be
major contributors inﬂuencing the rate of drug elution. Multiple
reducing agents were investigated and although DTT was thought
to interfere least in the elution process, was implicated in retarding
drug elution from high-BALC containing formulations due to
adduct formation at the surface of the beads which could interfere
with drug diffusion processes (Begg and Speicher 1999; Li et al.,
2001; Shu et al., 2003; Antelman et al., 2009; Srivastava et al.,
2011). In a simple proof-of-concept study it was demonstrated that
the BALC bead systems were able to respond to the reductive
environment by cleavage of disulﬁde cross-links, opening of the
hydrogel matrix and subsequent increase in the percentage of drug
236 K. Ashraﬁ et al. / International Journal of Pharmaceutics 524 (2017) 226–237released in the early phase of drug delivery, exactly where it is
proposed as being essential for overcoming the chemoresistance
mechanisms.
5. Conclusion
This study has demonstrated that Drug-eluting Embolisation
Beads based on BALC have the potential to be bioresponsive to
metabolic changes in the body and to modulate drug release
accordingly (You et al., 2010). They offer a novel mechanism of
hypoxia-mediated biodegradation, tunable by virtue of the BALC
content and unlike current systems which rely on hydrolytic and/
or enzymatic degradation (Weng et al., 2013a,b).
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